Rhetorical Friday, 06/26/20 11:21:09 AM Re: radly post# 6436 Post # of 6463 I'm not surprised that Ekso device got this clearance while others have not. I'd point to the fact that EksoNR senses and responds hundreds of times per second. This, combined with Ekso's integration of Functional Electronic Stimulation (FES) speak volumes to me. I think their work in these areas shows the way they approach the problem. I think they are deeply concerned with the nerve signaling and being able to work in similar frequency regimes. If you recognize this as value through the understanding the biomechanics, I think you'll see Ekso's value. Their stock has a major discrepancy (even still I'd contend) between value and price. This price is not the fault of the company, but the lack of investors who can't possibly recognize or understand why the value exists. Now we have bump from FDA clearance, but what is really going behind the FDA rationale and why Ekso has the better products is really the more important picture to me. Even so, if your truly LONG - you may still well come out ahead in the future. If this is a rocket launch, I'd say these are just the ignition sparks. Netflix's Space Force episode 5 has the crux of the episode featured around picking the right exoskeleton. Pretty cool. I'm long EKSO P.S. A recent Voices From DARPA epidosde was about vagus nerve signaling via stimulation and how this might be able to treat diabetes, ptsd, rls, irritable bowel - and is already approved for depression and epilepsy. I don't mean to get off topic, just to say that our understanding in nerve signaling in relation to medicine (as Ekso is involved in) is moving very rapidly and could be an entirely new paradigm being ushered in. I don't see other exoskeleton companies as being as far ahead as Ekso in this regard.